Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 23;11(2):e006530. doi: 10.1136/jitc-2022-006530

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

FCGR3A/2A/2C genotypes and outcome. A, D, E) There were no differences in response to treatment type based of FCGR3A/2A genotype status, and no differences in response rate (A). A trend toward improved EFS (D) and OS (E) was detected for patients with the high-affinity genotype for FCGR3A and FCGR2A (‘FCGR3A/2A high’) following treatment with chemoimmunotherapy as compared with I/T/TEMS (black solid line vs red solid line; EFS: p=0.06, OS: p=0.05). However, EFS among those with the FCGR3A/2A Low genotype was also significantly improved among based on receipt of I/T/DIN/GM-CSF versus I/T/TEMS (black dashed line vs red dashed line; p=0.02). B, F, G) There were no differences in response to treatment type based on FCGR3A/2C genotype status, and there are no differences in response rate (B) Patients with a high-affinity genotype for FCGR3A and FCGR2C (‘FCGR3A/2C high’) had significantly improved EFS (F) and a trend toward improved OS (G) when treated with immunotherapy as compared with I/T/TEMS (black solid line vs red solid line; EFS: p=0.04, OS: p=0.11). However, those with the FCGR3A/2C Low genotype also showed a trend toward improved EFS when treated with I/T/DIN/GM-CSF versus I/T/TEMS (black dashed line vs red dashed line; p=0.09). C, H, I) There were no differences in response to treatment type based on FCGR3A/2A/2C genotype status, and there were no differences in response rate (C) Patients with the a high-affinity genotype for FCGR3A, FCGR2A and FCGR2C (‘FCGR3A/2A/2C high’) had a trend for improved EFS (H) and significantly improved OS (I) when treated with I/T/DIN/GM-CSF vs I/T/TEMS (black solid line vs red solid line; EFS: p=0.06, OS: p=0.05), however, improved EFS was also detected in those with the FCGR3A/2A/2C low genotype when treated with I/T/DIN/GM-CSF versus I/T/TEMS (black dashed line vs red dashed line; p=0.02). DIN, dinutuximab; EFS, event-free survival; GM-CSF, granulocyte macrophage colony-stimulating factory; I/T, irinotecan and temozolomide; OS, overall survival; PFS, progression-free survival; TEMS, temsirolimus.